Drug Profile

OTOF GT

Alternative Names: OTOF-GT; SENS-501

Latest Information Update: 11 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Institut Pasteur
Developer Sensorion
Class Gene therapies
Mechanism of Action Gene transference; OTOF protein expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Deafness
New Molecular Entity No

Highest Development Phases

Phase I/II Deafness

Most Recent Events

08 Dec 2025 Updated adverse events and efficacy data from a phase-I/II trial in Deafness released by Sensorion
17 Sep 2025 Data from Cohort 2 in phase I/II Audiogene clinical trial at the higher dose are currently being collected, with a Data Monitoring Committee review expected by late second half of 2025
01 Jul 2025 Efficacy and adverse event data from phase from-I/II clinical trials in Deafness released by Sensorion

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com